Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Vastra Gotaland Region
Travera Inc
Endeavor Biomedicines, Inc.
University Hospital, Lille
PrECOG, LLC.
Lumicell, Inc.
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
Ipsen
Groupe Francais De Pneumo-Cancerologie
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
PharmaMar
Azienda USL Reggio Emilia - IRCCS
Columbia University
University Hospital Southampton NHS Foundation Trust
Memorial Sloan Kettering Cancer Center